Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04194398
Other study ID # OCS-LUN-122018
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 31, 2018
Est. completion date September 30, 2021

Study information

Verified date February 2022
Source TransMedics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Collection of five year follow-up data on patients who have already participated in the EXPAND Lung trial and have had transplants with donor lungs preserved on the OCS Lung System.


Description:

The purpose of this continuation study is to collect five year follow-up data on patients who have already participated in the EXPAND Lung trial and have had transplants with donor lungs preserved on the OCS Lung System. The EXPAND Lung trial results have been presented and have shown positive results in the use of expanded criteria donor lungs and patient follow-up, post-transplant. The current study is being conducted to continue to collect follow-up on participants in the EXPAND study, in order to evaluate long-term patient survival status and BOS diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date September 30, 2021
Est. primary completion date September 30, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Registered male or female primary double lung transplant candidate - Age =18 years old - Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information Exclusion Criteria: - Prior solid organ or bone marrow transplant - Single lung recipient - Chronic use of hemodialysis or diagnosis of chronic renal insufficiency

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OCS Lung System
Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.

Locations

Country Name City State
Belgium Hospitals Leuven Leuven
Germany Hannover Medical School Hannover
United States Massachusetts General Hospital Boston Massachusetts
United States Duke University Medical Center Durham North Carolina
United States University of California at Los Angeles Los Angeles California
United States University of Minnesota Minneapolis Minnesota
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States University of California at San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
TransMedics

Countries where clinical trial is conducted

United States,  Belgium,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient and graft survival Survival of graft and survival as evaluated at follow-up visit/call with patient or health care provider. 2 years
Primary Patient and graft survival Survival of graft and survival as evaluated at follow-up visit/call with patient or health care provider. 3 years
Primary Patient and graft survival Survival of graft and survival as evaluated at follow-up visit/call with patient or health care provider. 4 years
Primary Patient and graft survival Survival of graft and survival as evaluated at follow-up visit/call with patient or health care provider. 5 years
Primary Presence or absence of bronchiolitis obliterans sydrome (BOS) Evaluation of BOS as determined by follow-up evaluation visit/call with patient or health care provider. 2 years
Primary Presence or absence of bronchiolitis obliterans sydrome (BOS) Evaluation of BOS as determined by follow-up evaluation visit/call with patient or health care provider. 3 years
Primary Presence or absence of bronchiolitis obliterans sydrome (BOS) Evaluation of BOS as determined by follow-up evaluation visit/call with patient or health care provider. 4 years
Primary Presence or absence of bronchiolitis obliterans sydrome (BOS) Evaluation of BOS as determined by follow-up evaluation visit/call with patient or health care provider. 5 years